Former UFC interim lightweight champion Dustin Poirier used his recent appearance on The Joe Rogan Experience to spotlight peptides, describing them as recovery tools that could have prolonged his career. Poirier, who retired earlier this year, said he now uses multiple peptides and “feels great,” adding that he wishes he had access to them during his fighting years.
“Yeah, I’m on a bunch of peptides. Yeah, peptides are the way to go. And I feel great. Honestly, I wish I could have been on this when I was fighting, man,” Poirier told Rogan. “Especially like the growth hormone releasing stuff like tesamorelin. I could have pushed hard every day, man. As I got older, it got harder.”
In the conversation, Poirier singled out tesamorelin, a growth hormone‑releasing peptide, and BPC-157, a compound studied for soft tissue healing. He emphasized that these substances don’t provide a performance boost in terms of speed or strength, but rather help athletes recover from the constant injuries sustained in training. “All it does is help your body recover,” Poirier said, noting that fighters endure daily damage from leg kicks, arm bars, and joint strain.
Poirier and Rogan discussed how peptides occupy a gray zone in sports regulation. While creatine and protein powders are widely accepted, BPC-157 is banned under anti‑doping rules despite its reputation for aiding recovery. Rogan compared the stigma around peptides to creatine in the 1990s, when it was wrongly equated with steroids before becoming mainstream.
The exchange highlights a growing debate in combat sports: whether recovery‑focused peptides should remain prohibited despite not directly enhancing performance metrics. For fighters, the appeal is clear — faster healing means more consistent training and potentially longer careers. For regulators, the concern is maintaining fairness and safety in competition.
The Mechanics of Accelerated Healing
Science is increasingly uncovering why athletes report such rapid recovery using these compounds. In preclinical models, BPC-157 has shown a powerful ability to accelerate tissue repair by triggering angiogenesis—the formation of new blood vessels. This process delivers vital nutrients directly to damaged sites, significantly boosting muscle, tendon, and ligament healing. Furthermore, data from sports medicine reviews indicates that the peptide works by upregulating cellular growth factors and safely dialing down localized inflammation. Excitement is building around its human potential, especially as pioneering companies launch randomized, double-blind human clinical trials to officially track BPC-157’s efficacy on acute athletic strains.
Simultaneously, growth hormone secretagogues like tesamorelin are backed by substantial data proving their ability to build lean body mass. Studies tracking its use—including research listed on ClinicalTrials.gov—reveal that tesamorelin stimulates natural growth hormone secretion and elevates insulin-like growth factor-1 (IGF-1). A study published in the literature, such as The Effects of Tesamorelin on Phosphocreatine Recovery, demonstrated that this elevation correlates with enhanced mitochondrial function. This cellular optimization allows muscles to replenish phosphocreatine levels much faster after exertion, providing a legitimate blueprint for why athletes experience shortened recovery windows and improved physical resilience.
Cultural Shift in Supplement Perception
By framing peptides alongside creatine, Poirier underscored how perceptions of supplements evolve over time. What was once considered “cheating” can later be recognized as safe and beneficial. His comments reflect a broader cultural shift, as peptides move from niche medical research into mainstream athletic conversation.
For the peptide industry, Poirier’s remarks represent a high‑profile endorsement that could accelerate public awareness. For combat sports, they reignite the debate over where recovery ends and performance enhancement begins.